Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
H2 receptor antagonist that inhibits OCT2 directly by competing for binding sites, reducing the transport of substrates recognized by OCT2. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
URAT1 inhibitor indirectly influencing OCT2 by reducing renal excretion and subsequently elevating systemic levels of substrates for OCT2. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $67.00 $161.00 $255.00 $721.00 $3401.00 | 4 | |
Antibiotic inhibiting OCT2 by directly interfering with its transport activity, particularly impacting organic cation substrates. | ||||||
S/GSK1349572 | 1051375-16-6 | sc-364605 sc-364605B sc-364605A | 5 mg 50 mg 200 mg | $374.00 $1514.00 $4214.00 | ||
Integrase inhibitor with an indirect impact on OCT2 by influencing the P-glycoprotein (P-gp) efflux pump, affecting the disposition of drugs recognized by both P-gp and OCT2. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Antiarrhythmic agent directly inhibiting OCT2 by competing for substrate binding sites, reducing the transport of cationic drugs by OCT2. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker impacting OCT2 indirectly by inhibiting the activity of P-glycoprotein (P-gp), a transporter that can affect the disposition of substrates recognized by both P-gp and OCT2. | ||||||
Famotidine | 76824-35-6 | sc-205691 sc-205691A | 500 mg 1 g | $65.00 $111.00 | ||
H2 receptor antagonist inhibiting OCT2 directly by competing for binding sites, reducing the transport of cationic substrates by OCT2. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $80.00 $238.00 $825.00 | 5 | |
Antiprotozoal agent with an indirect impact on OCT2 by inhibiting the P-glycoprotein (P-gp) efflux pump, affecting the disposition of drugs recognized by both P-gp and OCT2. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker with an indirect effect on OCT2 by inhibiting the activity of NHE3, a sodium-hydrogen exchanger, altering the cellular environment and potentially affecting OCT2 activity. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Antibiotic impacting OCT2 indirectly by inducing the expression of efflux transporters, such as P-glycoprotein (P-gp), which can alter the disposition of substrates recognized by both P-gp and OCT2. | ||||||